Trial Profile
Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs PR1 peptide vaccine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 11 May 2009 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov (NCT00893997), due to slow accrual rates.
- 11 May 2009 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov (NCT00893997), due to slow accrual rates.
- 05 May 2009 New source identified and integrated (NCT00893997).